Posts by: Iqra Mumal, MSc

Iqra Mumal, MSc

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

March 23, 2020March 23, 2020

Emflaza Supply Not Affected by COVID-19 Pandemic, PTC Therapeutics Says

News

The supply of Emflaza (deflazacort), a treatment for people with Duchenne muscular dystrophy (DMD), will not be affected by the COVID-19 pandemic, according to PTC Therapeutics, its developer. In ... Read more

November 1, 2019November 1, 2019

PPMD Grants Funding for Research on Cardiac Health in People with Duchenne

News

Parent Project Muscular Dystrophy (PPMD) has awarded a total of $148,000 to researchers at Nationwide Children’s Hospital and the University of Missouri to help better understand and improve the ... Read more

November 14, 2018November 14, 2018

Extracellular RNAs in Urine May Work as Biomarker for Duchenne and Myotonic Dystrophy Patients

News

Extracellular RNAs found in urine may be able to serve as non-invasive biomarkers of how patients with muscular dystrophy — especially those with an adult-onset and the more common ... Read more

October 23, 2018October 24, 2018

Caregiving in DMD Has Significant Overall Impact on Everyday Life, Health, Review Shows

News

Taking care of patients with Duchenne muscular dystrophy (DMD) can have significant effects on caregivers, leading to a lower health‐related quality of life, poor sleep quality, depression, pain, stress, ... Read more

August 17, 2018August 17, 2018

WVE-210201 Receives FDA Orphan Drug, Rare Pediatric Disease Designations for DMD

News

Wave Life Sciences’ treatment candidate WVE-210201 has been granted both orphan drug designation and rare pediatric disease designation for the treatment of Duchenne muscular dystrophy (DMD) from the U.S. Food ... Read more

April 4, 2018April 4, 2018

New Gene Editing Strategy Leads to Much Longer Protein Production

News

American researchers have developed a new way of delivering a gene editing therapy that significantly increases the time a repaired gene can generate the protein that’s missing in a ... Read more

December 19, 2017December 19, 2017

Gene Therapy Approach Using HAC Vector May Work with Dystrophin Gene, Study Suggests

News

A new way of transferring the dystrophin gene — the largest known human gene — into muscle stem cells may be possible using the human artificial chromosome (HAC) vector, a ... Read more

December 18, 2017December 18, 2017

Problems in IL-6 Pathway Linked to Severe Symptoms of Congenital Myotonic Dystrophy in Study

News

Aberrant signaling in the IL-6 pathway, which is involved in muscle cell maturation, contributes to the severe symptoms seen in congenital myotonic dystrophy (CDM) patients, researchers in Japan report. The ... Read more

December 15, 2017December 15, 2017

Investigational Therapy SR8278 Shown to Regenerate Muscle in DMD Mice Study

News

Scientists at Saint Louis University believe that an investigational therapy called SR8278 holds potential for treating Duchenne muscular dystrophy (DMD) after it was shown to increase muscle function and decrease ... Read more